Drugs / IM19 CAR-T cells
Trials 4
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 01 trial | ||||||
| Phase 0 | NCT05480501 | Jul 2022 → Aug 2024 | leukemia | Beijing Immunochina Medical Science & Technology Co., Ltd. | Unknown | No outcome recorded |
| Phase 1/22 trials | ||||||
| Phase 1/2 | NCT05309213 | Apr 2022 → Apr 2025 | lymphoid leukemia | Beijing Immunochina Medical Science & Technology Co., Ltd. | Unknown | No outcome recorded |
| Phase 1/2 | NCT05155215 | Dec 2021 → Dec 2022 | immunoproliferative disorder, mantle cell lymphoma | Beijing Immunochina Medical Science & Technology Co., Ltd. | Unknown | No outcome recorded |
| Phase not applicable1 trial | ||||||
| — | NCT06513429 | Jul 2024 → Dec 2025 overdue | systemic lupus erythematosus | Peking University Third Hospital | Recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | IM19 CAR-T cells | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05480501 ↗ |
| Modality | Cell therapy | “IM19 CAR-T cells” NCT05155215 ↗ |
| Route | Intravenous | “IM19 CAR-T cells by intravenous infusion.” NCT06513429 ↗ |